Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
Replimune Group, Inc. REPL

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Apr 10, 2026 8-K 17 signals fired · top 15
Core
Clinical Trial Result Combination Therapy Mentioned Indication Expansion Enrollment Failure Clinical Hold Regulatory Designation Only
Biotech Risk
Crl Received Trial Endpoint Missed Clinical Hold Active
Other
Interim Data Positive Patient Retention High Workforce Reduction Restructuring Plan Checkpoint Inhibitor Program Priority Review Or Pdufa Disclosed Fda Aligned
Feb 3, 2026 10-Q 52 signals fired · top 15
Other
Net Loss Reported Financing Activities Cash Flow Disclosure Cash Flow Statement Investing Activities Liquidity Position Snapshot Disclosed Material Weakness In Internal Controls Disclosed Share Withholding Tax Settlement Institutional Investment Valuation Allowance Deferred Tax Disclosure Other Income Expense Disclosure Ipo Or Capital Raising Completion Stock Option Intrinsic Value Disclosure Shares Outstanding Disclosure Capitalized Software Amortization Disclosed Protocol Amended
Core
Clinical Trial Result
Feb 3, 2026 8-K 4 signals fired
Other
Priority Review Or Pdufa Disclosed
Core
Near Term Regulatory Decision Indication Expansion
Biotech Risk
Crl Received
Jan 12, 2026 8-K 13 signals fired
Core
Clinical Trial Result Lead Asset Progress Combination Therapy Mentioned Clinical Hold
Other
Interim Data Positive Kol Endorsement Safety Differentiated Publication Positive Fda Aligned Patient Retention High Rmat Designation Received Board Committee Member Listing
Biotech Risk
Clinical Hold Active
Nov 6, 2025 10-Q 40 signals fired · top 15
Other
Net Loss Reported Material Weakness In Internal Controls Disclosed Financing Activities Cash Flow Disclosure Cash Flow Statement Investing Activities Litigation Defense Assertion Liquidity Position Snapshot Disclosed Valuation Allowance Deferred Tax Disclosure Institutional Investment Other Income Expense Disclosure Ipo Or Capital Raising Completion Shares Outstanding Disclosure Capitalized Software Amortization Disclosed Priority Review Or Pdufa Disclosed
Core
Clinical Trial Result Near Term Regulatory Decision
Nov 6, 2025 8-K 6 signals fired
Other
Priority Review Or Pdufa Disclosed Fda Aligned
Biotech Risk
Crl Received Clinical Hold Active
Core
Near Term Regulatory Decision Indication Expansion
Oct 20, 2025 8-K 11 signals fired
Other
Priority Review Or Pdufa Disclosed Safety Differentiated Checkpoint Inhibitor Program Fda Aligned
Core
Near Term Regulatory Decision Combination Therapy Mentioned Indication Expansion Clinical Hold
Biotech Risk
Crl Received Clinical Hold Active Accelerated Approval